Sanolla

Company Overview

Snapshot

Founded in April 2016 by Doron Adler and Dudu Linhard, Sanolla operates with 11–50 employees. The company has raised $16 million across 6 funding rounds from 4 investors.

Business overview

Sanolla develops smart diagnostic solutions for physicians and patients, focusing on the early assessment and monitoring of cardiopulmonary conditions such as congestive heart failure, pneumonia, asthma, chronic obstructive pulmonary disease, and COVID-19. Its core technology leverages AI-powered detection and analysis of body infrasounds and other vital signs like ECG, heart rate, oxygen level, body temperature, and respiratory cycle. Sanolla's products, including VoqX, SonoX, and PyXy, aim to provide immediate and accurate assessments, reduce unnecessary in-clinic visits, and lower infection exposure risks. The company operates in the Health Tech & Life Sciences sector, specifically within Medical Devices and Digital Healthcare, serving markets across North America, Europe, Southeast Asia, and Oceania.

Strategic signal

In September 2025, Sanolla is set to launch its VoqX smart AI-powered stethoscope, which offers full-spectrum auscultation. This product launch signifies a major advancement in diagnostic tools, potentially transforming clinical practice by providing more comprehensive and accurate data for cardiopulmonary conditions. For investors, this indicates strong product development momentum and a strategic move to capture a larger share of the digital health and medical device markets with innovative AI-driven solutions.

Company Intelligence Q&A

What is Sanolla's primary focus in healthcare diagnostics?

Sanolla specializes in providing smart diagnostic solutions for the early assessment and monitoring of cardiopulmonary conditions, including congestive heart failure, pneumonia, asthma, and COVID-19.

What is the core technology behind Sanolla's diagnostic products?

Sanolla's technology is based on AI-powered detection and analysis of previously inaccessible body infrasounds, combined with other vital signs such as ECG, heart rate, oxygen level, body temperature, and respiratory cycle.

When did Sanolla receive FDA clearance for its AI-powered infrasound stethoscope?

In April 2022, Sanolla received FDA clearance for the world's first AI-powered infrasound stethoscope.

Which of Sanolla's products is designed for full-spectrum auscultation?

Sanolla's VoqX smart AI-powered stethoscope is designed to offer full-spectrum auscultation, advancing clinical practice with its advanced capabilities.

Has Sanolla received any grants from the Israel Innovation Authority?

Yes, Sanolla received a grant from the Israel Innovation Authority in January 2017, another in January 2018, and a third in January 2020.